2016 International Congress Archives - Page 13 of 207

12:00pm-1:30pm: Correlation between self-perceived balance confidence, postural control, gait and quality of life of individuals with Parkinson’s disease

J.E. Pompeu, K.G. Silva, T.B. Freitas, F. Doná, C. Torriani-Pasin, R.A. Nuvolini (São Paulo, Brazil)

Phenomenology and clinical assessment of movement disorders · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Cortical atrophy in cognitively impaired Parkinson’s disease patients

M.M. Almuqbel, T.R. Melzer, D.J. Myall, M.R. MacAskill, L. Livingston, K. Wood, T.L. Pitcher, R.J. Keenan, J.C. Dalrymple-Alford, T.J. Andrson (Christchurch, New Zealand)

Parkinson's disease: Neuroimaging and neurophysiology · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Cortical excitability in patients with Parkinson’s disease on levodopa carbidopa intestinal gel thereapy

S.D. Kim, S. Vucic, N. Mahant, M.C. Kiernan, V.S.C. Fung (Sydney, Australia)

Parkinson's disease: Neuroimaging and neurophysiology · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Cortical grey matter atrophy in the motor system in Friedreich ataxia: The IMAGE-FRDA study

I. Harding, L. Selvadurai, L. Corben, M. Stagnitti, E. Storey, G. Egan, M. Delatycki, N. Georgiou-Karistianis (Melbourne, Australia)

Ataxiz, Choreas

12:00pm-1:30pm: Cortical phase amplitude coupling (PAC) identifies patterns in clinical states of Parkinson’s disease (PD) using magnetoencephalography (MEG)

E. Peña, S.A. Mian, L. Rosedahl, F.A.I. Mohammed, T.M. Mohammad, M.D. Johnson, J.A. Bajwa (Minneapolis, MN, USA)

Parkinson's disease: Neuroimaging and neurophysiology · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Cortical thinning associated with mild cognitive impairment in Parkinson’s disease

S. Galantucci, F. Agosta, T. Stojkovic, I. Petrovic, E. Stefanova, E. Canu, M. Copetti, V.S. Kostic, M. Filippi (Milan, Italy)

Parkinson's disease: Neuroimaging and neurophysiology · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Cortico-striatal functional connectivity in the premanifest and manifest period of Huntingtons disease measured with high-field functional magnetic resonance imaging

M. Kronenbuerger, J. Hua, C.A. Ross (Baltimore, MD, USA)

Huntington's disease · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Critical path for Parkinson’s II: Global regulatory agencies support the use of dopamine transporter neuroimaging as an enrichment biomarker to enable clinical trials in early Parkinson’s disease

D.T. Stephenson, S. Arneric, D. Babcock, P. Cole, T. Comery, M.F. Gordon, D. Grosset, D. Hill, S.Z. Imam, C.R. Jarecke, V. Kern, D. Matthews, R. Meibach, K. Romero, A. Roach, D. Russell, J. Seibyl, P. Sherwin, B.A. Sieber, L. Slicker, C. Sur, K. Marek (Tucson, AZ, USA)

Parkinson's disease: Neuroimaging and neurophysiology · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: CSF inflammatory and cell death biomarkers in Huntington’s disease – An exploratory cross-sectional study

F.B. Rodrigues, L. Byrne, S.J. Tabrizi, H. Zetterberg, E. Wild (London, United Kingdom)

Huntington's disease · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Cytokines in CSF and plasma as potential biomarkers for PD cognitive impairment

M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

Parkinson's disease: Cognition · Exhibit Hall located in Hall B, Level 2